Skip to content

Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Sepsis and Multiple Sclerosis

Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Sepsis and Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068504
Enrollment
Unknown
Registered
2023-02-21
Start date
2023-02-21
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis and Multiple Sclerosis

Interventions

Group 1:none
Group 2:none
Group 3:none

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. The age of the patient is >= 18 years old; 2. Admission = 2 points): determination of infection focus: clear infection focus such as respiratory tract infection, urinary tract infection, intestinal infection, etc., and exclude central nervous system infection focus ; 4. Clinically diagnosed patients with multiple sclerosis who meet the clinical diagnostic criteria for multiple sclerosis; 5. Patients and their families have informed consent to participate in the research project; 6. Be able to communicate briefly with researchers and complete the evaluation of relevant scales.

Exclusion criteria

Exclusion criteria: 1. Patients with primary central nervous system diseases (such as cerebral hemorrhage, cerebral infarction, brain trauma, etc.); 2. Patients have previously suffered from mental or neurological diseases (for example, intracranial tumors); 3. There is clear evidence of encephalitis/meningitis; 4. Disturbance of consciousness and changes in mental state caused by acute encephalopathy caused by other reasons. Including metabolic encephalopathy, blood electrolyte disturbance, toxic encephalopathy, primary central nervous system disease, and sedative and hypnotic drug interference, etc.; 5. Antibiotics, hormones and other immunosuppressive drugs were used before admission; 6. Renal replacement therapy such as hemofiltration and hemodialysis; 7. Tumors, autoimmune diseases, liver cirrhosis, uremia, etc.; 8. Recent history of blood transfusion; 9. Patients or family members refuse to participate in this study.

Design outcomes

Primary

MeasureTime frame
Cytokine;chemokine protein;core gene mRNA and other levels;

Countries

China

Contacts

Public ContactLi Gong

The Third Xiangya Hospital of Central South University

ligong@csu.edu.cn+86 134 6751 1233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026